NCT04963790

Brief Summary

The approval and distribution of COVID-19 vaccines is an important milestone in the fight against the pandemic. However, although vaccines are widely recognized as a key public health measure to control infectious disease, there are still people who remain hesitant to get vaccinated. In Canada, 83% of Canadian adults have received or are willing to receive the vaccine. However, nearly 20% of adults and a larger proportion of parents of younger children remain concerned about receiving vaccines. In the context of a project to enable family physicians to identify vaccine-hesitant patients and deliver a tailored COVID-19 vaccination outreach campaign, the Canadian Practice Information Network, a tool for primary care providers to communicate with their patients, will be used to engage and address vaccination hesitancy in Canada. The study will identify information needs about COVID-19 vaccination among community-dwelling patients in three Canadian provinces and will assess the effectiveness of a tailored COVID-19 vaccine digital health communication strategy for primary care practices to address vaccination hesitancy and improve COVID-19 vaccination uptake. A two-arm cluster randomized trial design will be conducted in primary care practices in three Canadian provinces: Ontario, British Columbia, and New Brunswick. The study will use a convenience sample of primary care practice in these provinces. Recruited participants will be randomly allocated to the intervention and control groups. Patients assigned to the control group will receive health messages unrelated to the COVID-19. Participants in the intervention group will receive a series of tailored messages on COVID-19 vaccination targeting the main factors for hesitancy to address their concerns and persuade them to receive the COVID-19 vaccine. Aggregated survey responses across practices will be used to create segments of unvaccinated patients reflecting age, language, education level, rurality, sex, gender, ethnicity, and their attitudes or reasons for vaccine hesitancy or access barriers. Then, tailored messages will be created in a way that is meaningful to the recipients in the different segments. The primary outcome is the proportion of vaccine-hesitant individuals who receive a COVID-19 vaccine during the intervention period. The secondary outcome is the overall COVID-19 vaccine uptake.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable covid19

Timeline
Completed

Started Nov 2021

Typical duration for not_applicable covid19

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 14, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 15, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

November 14, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 24, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 14, 2023

Completed
Last Updated

May 20, 2024

Status Verified

May 1, 2024

Enrollment Period

1.4 years

First QC Date

July 14, 2021

Last Update Submit

May 17, 2024

Conditions

Keywords

COVID-19vaccine hesitancycluster randomized trialtailored messaginghealth communication

Outcome Measures

Primary Outcomes (1)

  • Proportion of hesitant individuals who received a COVID-19 vaccine

    The proportion of vaccine hesitant individuals who receive a COVID-19 vaccine during the intervention period

    10 months

Secondary Outcomes (1)

  • Individual willingness to receive a COVID-19 vaccine

    10 months

Study Arms (2)

Tailored COVID-19 vaccine messaging

EXPERIMENTAL

Based on the created segments of hesitant participants (reflecting age, language, education level, rurality, sex, gender, ethnicity, and attitudes or reasons for vaccine hesitancy) in the intervention group, a series of tailored messages that are meaningful to the recipients in the different segments will be created and sent to address the factors influencing the willingness to be vaccinated and persuade them to get the COVID-19 vaccine.

Behavioral: Tailored COVID-19 vaccine messages

Other health-related messaging

ACTIVE COMPARATOR

Patients assigned to the control group will receive health messages unrelated to COVID-19.

Other: Other health messages

Interventions

Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.

Tailored COVID-19 vaccine messaging

Other health messages unrelated to COVID-19 will be sent to participants in the control arm

Other health-related messaging

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Non-vaccinated adults
  • Enrolled in a participating CPIN primary care practice

You may not qualify if:

  • Patients who don't speak one of Canada's official languages (English and French)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eastern Ontario Health Unit

Cornwall, Ontario, K6J 5T1, Canada

Location

Related Links

MeSH Terms

Conditions

COVID-19Vaccination Hesitancy

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesVaccination RefusalTreatment RefusalTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

  • Sharon Johnston, MD

    Institut du Savoir Montfort

    PRINCIPAL INVESTIGATOR
  • William Hogg, MD

    Institut du Savoir Montfort

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Patients in the intervention group will receive a series of tailored messages on COVID-19 vaccination. Patients assigned to the control group will receive health messages unrelated to the COVID-19.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 14, 2021

First Posted

July 15, 2021

Study Start

November 14, 2021

Primary Completion

April 24, 2023

Study Completion

July 14, 2023

Last Updated

May 20, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations